These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 34893348)

  • 1. Real-world impact of mepolizumab in patients with life-threatening asthma: US insurance claims database analysis.
    Silver J; Molfino N; Bogart M; Packnett ER; McMorrow D; Wu J; Hahn B
    Clin Ther; 2021 Dec; 43(12):2064-2073. PubMed ID: 34893348
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reduction in asthma exacerbation rate after mepolizumab treatment initiation in patients with severe asthma: A real-world database study in Japan.
    Nagase H; Tamaoki J; Suzuki T; Nezu Y; Akiyama S; Cole AL; Yang S; Mu G; Katsumata M; Komatsubara M; Alfonso-Cristancho R
    Pulm Pharmacol Ther; 2022 Aug; 75():102130. PubMed ID: 35714883
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of mepolizumab on exacerbations in severe asthma: Results from a U.S. insurance claims data base.
    Ortega H; Hahn B; Bogart M; Bell CF; Bancroft T; Chastek B; Llanos JP
    Allergy Asthma Proc; 2020 Sep; 41(5):341-347. PubMed ID: 32867888
    [No Abstract]   [Full Text] [Related]  

  • 4. Impact of mepolizumab in patients with high-burden severe asthma within a managed care population.
    Lugogo NL; Bogart M; Corbridge T; Packnett ER; Wu J; Hahn B
    J Asthma; 2023 Apr; 60(4):811-823. PubMed ID: 35853158
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Real-World Reductions in Oral Corticosteroid Use in the USA Following Mepolizumab Therapy for Severe Asthma.
    Silver J; Bogart M; Packnett E; Wu J; McMorrow D; Hahn B
    J Asthma Allergy; 2020; 13():689-699. PubMed ID: 33364788
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of Mepolizumab on Exacerbations in the US Medicare Population.
    Sethi S; Bogart M; Corbridge T; Cyhaniuk A; Hahn B
    J Allergy Clin Immunol Pract; 2023 Feb; 11(2):546-554.e2. PubMed ID: 36377070
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A real-world study of inhaled corticosteroid use in patients with severe eosinophilic asthma treated with mepolizumab.
    Corren J; Silver J; Molfino NA; Bogart M; Packnett E; McMorrow D; Wu J; Hahn B
    Ann Allergy Asthma Immunol; 2022 Feb; 128(2):184-192.e1. PubMed ID: 34774737
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term Safety and Clinical Benefit of Mepolizumab in Patients With the Most Severe Eosinophilic Asthma: The COSMEX Study.
    Khurana S; Brusselle GG; Bel EH; FitzGerald JM; Masoli M; Korn S; Kato M; Albers FC; Bradford ES; Gilson MJ; Price RG; Humbert M
    Clin Ther; 2019 Oct; 41(10):2041-2056.e5. PubMed ID: 31447130
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Real-World Effectiveness of Mepolizumab in Patients with Severe Asthma: An Examination of Exacerbations and Costs.
    Llanos JP; Ortega H; Bogart M; Packnett ER; Manjelievskaia J; Bell CF; Hahn B
    J Asthma Allergy; 2020; 13():77-87. PubMed ID: 32099413
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Real-World Effectiveness of Mepolizumab in Patients with Allergic and Non-Allergic Asthma.
    Silver J; Steffens A; Chastek B; Deb A
    J Asthma Allergy; 2024; 17():261-271. PubMed ID: 38544676
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term retention rate of mepolizumab treatment in severe asthma: a 36-months real-life experience.
    Matucci A; Vivarelli E; Bormioli S; Francesca N; Chiccoli F; Valentina M; Francesca G; Oliviero R; Parronchi P; Vultaggio A
    J Asthma; 2023 Jan; 60(1):158-166. PubMed ID: 35112934
    [No Abstract]   [Full Text] [Related]  

  • 12. REal worlD Effectiveness and Safety of Mepolizumab in a Multicentric Spanish Cohort of Asthma Patients Stratified by Eosinophils: The REDES Study.
    Domingo Ribas C; Carrillo Díaz T; Blanco Aparicio M; Martínez Moragón E; Banas Conejero D; Sánchez Herrero MG;
    Drugs; 2021 Oct; 81(15):1763-1774. PubMed ID: 34586602
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Real-world mepolizumab in the prospective severe asthma REALITI-A study: initial analysis.
    Harrison T; Canonica GW; Chupp G; Lee J; Schleich F; Welte T; Valero A; Gemzoe K; Maxwell A; Joksaite S; Yang S; Howarth P; Van Dyke MK
    Eur Respir J; 2020 Oct; 56(4):. PubMed ID: 32817259
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of mepolizumab treatment in oral corticosteroid-dependent severe eosinophilic asthma patients with chronic rhinosinusitis with nasal polyps: single center, real life study.
    Yilmaz I; Türk M; Nazik Bahçecioğlu S; Tutar N; Gülmez I
    Turk J Med Sci; 2020 Apr; 50(2):433-441. PubMed ID: 32093447
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A cost comparison of benralizumab, mepolizumab, and dupilumab in patients with severe asthma: A US third-party payer perspective.
    Xu X; Schaefer C; Szende A; Genofre E; Katial R; Chung Y
    J Manag Care Spec Pharm; 2023 Nov; 29(11):1193-1204. PubMed ID: 37796731
    [No Abstract]   [Full Text] [Related]  

  • 16. Real-world effectiveness of mepolizumab in patients with severe asthma and associated comorbidities.
    Casale T; Molfino NA; Silver J; Bogart M; Packnett E; McMorrow D; Wu J; Hahn B
    Ann Allergy Asthma Immunol; 2021 Sep; 127(3):354-362.e2. PubMed ID: 34038773
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mepolizumab in Severe Eosinophilic Asthma: A 2-Year Follow-Up in Specialized Asthma Clinics in Greece: An Interim Analysis.
    Kallieri M; Zervas E; Katsoulis K; Fouka E; Porpodis K; Samitas K; Papaioannou AI; Kipourou M; Gaki E; Vittorakis S; Markatos M; Dimakou K; Ampelioti S; Koukidou S; Makris M; Ntakoula M; Mitrova MH; Glynos K; Antoniou KM; Gaga M; Tzanakis N; Markopoulou K; Papakosta D; Bakakos P; Loukides S
    Int Arch Allergy Immunol; 2020; 181(8):613-617. PubMed ID: 32570256
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Real-world effectiveness of mepolizumab in severe asthma and chronic rhinosinusitis in the United States: Impact of comorbidity and sinus surgery.
    Silver J; Deb A; Laliberté F; Gao C; Bhattacharyya N
    Int Forum Allergy Rhinol; 2024 Jan; 14(1):5-17. PubMed ID: 37365852
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mepolizumab Is an Effective Option in Severe Eosinophilic Asthma Regardless of Baseline Features: Single-Center Real-Life Data.
    Özdel Öztürk B; Yavuz Z; Eraslan D; Mungan D; Demirel YS; Aydın Ö; Sin BA; Bavbek S
    Int Arch Allergy Immunol; 2022; 183(5):526-538. PubMed ID: 34915496
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Severe eosinophilic asthma treated with mepolizumab stratified by baseline eosinophil thresholds: a secondary analysis of the DREAM and MENSA studies.
    Ortega HG; Yancey SW; Mayer B; Gunsoy NB; Keene ON; Bleecker ER; Brightling CE; Pavord ID
    Lancet Respir Med; 2016 Jul; 4(7):549-556. PubMed ID: 27177493
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.